This is a summary of the European public assessment report (EPAR) for Nuwiq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Nuwiq. For practical information about using Nuwiq, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Nuwiq can be used for all age groups.
Therapeutic Area (MeSH)
ATC Code
B02BD02
ATC Item
coagulation factor VIII
Pharmacotherapeutic Group
Blood coagulation factors
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| simoctocog alfa | N/A | Simoctocog alfa |
EMA Name
Nuwiq
Medicine Name
Nuwiq
Aliases
N/A